lymphocyte-specific protein tyrosine kinase inhibitors (A&G Pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namelymphocyte-specific protein tyrosine kinase inhibitors (A&G Pharmaceuticals)
Drug Alias NameLck tyrosine kinase inhibitor (A&G Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase LCK inhibitors
TargetsTyrosine-protein kinase LCK
Therapy Area/IndicationsInflammationArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesA&G Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesA&G Pharmaceutical
Active IndicationsN/A
Inactive IndicationsInflammationArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A